-
-
-
-
-
-
-
NewAmsterdam Pharma expects EMA decision on obicetrapib in 2H26
-
-
-
-
-
-
-
Wells Fargo Starts NewAmsterdam Pharma Co NV (NAMS) at Overweight
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)
-
-
-
-
-
-
-
NewAmsterdam Pharma (NAMS) appoints Adele Gulfo to Board
-
-
-
-
-
-
-
NewAmsterdam Pharma (NAMS) Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
-
-
-
-
-
-
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
-
-
-
423,329 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

